齐拉西酮与奥氮平治疗早期精神分裂症的疗效及安全性比较分析

胡乃启

[摘要] 目的 探讨齐拉西酮与奥氮平治疗早期精神分裂症的疗效及安全性比较分析。方法 便利选择2015年1月—2016年12月该院收治的116例早期精神分裂症患者，随机分为对照组和试验组，每组58例。对照组58例采用奥氮平治疗，试验组58例采用齐拉西酮治疗。比较两组患者临床疗效及自我管理能力的差异，并评价其不良反应情况。 结果 试验组患者临床总有效率高于对照组，分别为93.1%、77.6%，比较差异有统计学意义（P<0.05）；试验组治疗后自我管理能力评分为（76.72±5.83）分，显著高于对照组的（62.37±5.12）分，差异有统计学意义（P<0.05）；试验组患者不良反应发生率高于对照组，分别为5.2%、20.7%，比较差异有统计学意义（P<0.05）。结论 齐拉西酮较奥氮平治疗早期精神分裂癥临床疗效佳，其临床有效率高，自我管理能力高，不良反应少，值得临床选择。

[关键词] 齐拉西酮；奥氮平；早期精神分裂症；疗效；安全性

[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742（2017）05（c）-0116-03

[Abstract] Objective To study the comparative analysis of curative effect and safety of ziprasidone and olanzapine in treatment of early Schizophrenia. Methods 116 cases of patients with early schizophrenia admitted and treated in our hospital from January 2015 to December 2016 were conveniently selected and randomly divided into two groups with 58 cases in each， the control group were treated with olanzapine， while the test group were treated with ziprasidone， and the clinical curative effect and self-management ability were compared between the two groups， and the adverse reactions were evaluated. Results The total clinical effective rate in the test group was higher than that in the control group， which was respectively 93.1% and 77.6%， and there was statistical difference by comparison（P<0.05）， and the self-management ability score after treatment in the test group was obviously higher than that in the control group[（76.72±5.83）points vs （62.37±5.12）points]， and the difference was statistically significant（P<0.05）， and the incidence rate of adverse reactions in the test group was higher than that in the control group， which was respectively 5.2% and 20.7%， and the difference was statistically significant（P<0.05）. Conclusion The clinical curative effect of ziprasidone in treatment of early schizophrenia is better than that of olanzapine with high clinical effective rate， high self-management ability and few adverse reactions， which is worth clinical selection.

[Key words] Ziprasidone； Olanzapine； Early schizophrenia； Curative effect； Safety

精神分裂症是临床上常见的精神性疾病之一[1-2]，其发病率高、慢性进展，治疗后易复发，给患者生活质量及身心健康带来严重不利影响。患者主要以思维、情感障碍等临床表现，早期精神分裂症患者常采用抗精神药物治疗该疾病，而选择有效、不良反应低的抗精神药物对患者治疗和预后具有重要价值。该研究便利选择2015年1月—2016年12月该院收治的116例早期精神分裂症患者作为研究对象，探讨齐拉西酮与奥氮平治疗早期精神分裂症的疗效及安全性，现报道如下。

1 资料与方法

1.1 一般资料

便利选取该院收治的116例早期精神分裂症患者，随机分为两组。试验组58例，男23例，女35例；年龄26～67岁，平均年龄（43.26±4.75）岁；病程为0.6～3.6年，平均病程（1.95±0.72）年；对照组58例，男21例，女37例；年龄25～68岁，平均年龄（43.43±4.69）岁；病程为0.4～3.7年，平均病程（1.94±0.68）年；入组标准：①患者均符合早期精神分裂症的诊断标准[3]；②无重要脏器功能障碍者；③近2周未服用抗精神药物者；……